Replies to post #187932 on Biotech Values

[genisi]

Re: safety halt for B-I’s BACE drug due to skin reactions

My first thought was this ß-secretase inhibitor might cause an adverse effect similar to that of the late ?-secretase - semagacestat.

[DewDiligence]

VTAE -25% on phase-2 data for VTP-34072 in overweight T2D:

http://finance.yahoo.com/news/vitae-pharmaceuticals-announces-top-line-103200760.html

Primary efficacy data (fasting plasma glucose) from the metformin arm did not meet Boehringer Ingelheim's predefined endpoint criteria. Data from the placebo-controlled monotherapy arm of the trial, which is still ongoing, are expected to be reported later this year. Together, these data sets will be used by Boehringer Ingelheim to determine appropriate next steps for BI187004/VTP-34072.